^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    HER2- and HER3-primed dendritic cells

    i
    Other names: HER2- and HER3-primed dendritic cells
    Associations

    News

    Trials
    Company:
    H. Lee Moffitt Cancer Center and Research Institute
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    4ms
    DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial completion date: Apr 2025 --> Aug 2025
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER2- and HER3-primed dendritic cells
    12ms
    DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Suspended --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    HER2- and HER3-primed dendritic cells
    1year
    DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer (clinicaltrials.gov)
    P1, N=30, Suspended, H. Lee Moffitt Cancer Center and Research Institute | Recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2) • ERBB3 (V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 3)
    |
    HER-2 negative
    |
    HER2- and HER3-primed dendritic cells